Difficulty: Medium
Average Score: 64%
Practice
One of the following drugs may cause pyloric stenosis if administered to a premature infant
Correct answer
D
Rationale
In this scenario, the correct answer is D) dexamethasone. Pyloric stenosis is a condition characterized by the narrowing of the opening from the stomach to the small intestine (pylorus). Dexamethasone is a corticosteroid that can contribute to the development of pyloric stenosis in premature infants due to its effect on the muscular structure of the pylorus.
Option A) intravenous vitamin E is incorrect because it is not associated with causing pyloric stenosis in premature infants. Option B) indomethacin is typically used to treat patent ductus arteriosus in premature infants and is not linked to pyloric stenosis. Option C) enteric gentamicin is an antibiotic that is not known to cause pyloric stenosis in premature infants.
Educationally, understanding the potential side effects of medications in neonates and premature infants is crucial for healthcare providers working in pediatric settings. This knowledge ensures safe administration practices and helps in early identification of adverse reactions. It also highlights the importance of individualizing drug therapy based on patient factors such as age, weight, and gestational age to minimize risks and optimize outcomes in this vulnerable population.
Option A) intravenous vitamin E is incorrect because it is not associated with causing pyloric stenosis in premature infants. Option B) indomethacin is typically used to treat patent ductus arteriosus in premature infants and is not linked to pyloric stenosis. Option C) enteric gentamicin is an antibiotic that is not known to cause pyloric stenosis in premature infants.
Educationally, understanding the potential side effects of medications in neonates and premature infants is crucial for healthcare providers working in pediatric settings. This knowledge ensures safe administration practices and helps in early identification of adverse reactions. It also highlights the importance of individualizing drug therapy based on patient factors such as age, weight, and gestational age to minimize risks and optimize outcomes in this vulnerable population.